ConforMIS, Inc. (NASDAQ: CFMS) had its "buy" rating re-affirmed by analysts at Oppenheimer Holdings, Inc..
Last conformis, inc. earnings: 3/3 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: ir.conformis.com
Impact snapshot | Event time: | CFMS | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last price | ||
VWAP | ||
High:
|
Max up |
High:
|
Low:
|
Max down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
CFMS alerts
CFMS alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CFMS alerts
High impacting Conformis, Inc. news events
Weekly update
A roundup of the hottest topics
CFMS
News
- Conformis, Inc. to Release First Quarter 2021 Financial Results on May 5, 2021GlobeNewswire
- Conformis: Caution Warranted Following Another Underwhelming Quarter [Seeking Alpha]Seeking Alpha
- Clinical Study: Patient-Specific Total Knee Replacement with Conformis Technology Is More Cost-Effective Than with Leading Off-the-Shelf ImplantsGlobeNewswire
- Conformis, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/CFMS/price-target/">NASDAQ: CFMS</a>) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on MarketBeat
- Conformis, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/CFMS/price-target/">NASDAQ: CFMS</a>) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.MarketBeat
- More
CFMS
SEC Filings
- 4/6/21 - Form 4
- 3/30/21 - Form PRE
- 3/4/21 - Form S-8
- CFMS's page on the SEC website
- More